| Microenvironment shapes small-cell lung cancer neuroendocrine states and presents therapeutic opportunities P Desai, N Takahashi, R Kumar, S Nichols, J Malin, A Hunt, C Schultz, ... Cell Reports Medicine 5 (6), 2024 | | 2024 |
| Tazemetostat in combination with topotecan and pembrolizumab in patients with recurrent small cell lung cancer. PA Desai, N Takahashi, D Lissa, S Nichols, L Sciuto, ML Abel, ... Journal of Clinical Oncology 42 (16_suppl), TPS8130-TPS8130, 2024 | | 2024 |
| Hematology/oncology fellowship programs’ instagram presence. M Greenberg, P Ssentongo, S Mattikalli, E Tomasulo, PA Desai, ... Journal of Clinical Oncology 42 (16_suppl), 9047-9047, 2024 | | 2024 |
| Abstract CT257: Hyperprogressive disease following bintrafusp alfa and DNA damaging chemotherapy in relapsed small cell lung cancer B Schroeder, N Takahashi, H Yang, R Donahue, Z Skidmore, A Konicki, ... Cancer Research 84 (7_Supplement), CT257-CT257, 2024 | | 2024 |
| “Cross-over Effect” in survival curves with immune-checkpoint inhibition: Identifying ideal candidates for immunotherapy-only approaches in specific tumor histologies S Goyal, A Thomas, PA Desai Cancer Research 84 (6_Supplement), 7537-7537, 2024 | | 2024 |
| Author Correction: ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer CW Schultz, Y Zhang, R Elmeskini, A Zimmermann, H Fu, Y Murai, ... EMBO Molecular Medicine 16 (3), 664-664, 2024 | | 2024 |
| Microenvironment Shapes Small Cell Lung Cancer Neuroendocrine States and Presents Therapeutic Opportunities P Desai, N Takahashi, R Kumar, S Nichols, J Malin, A Hunt, C Schultz, ... bioRxiv, 2024.02. 09.579028, 2024 | | 2024 |
| Genomic alterations and transcriptional phenotypes in circulating tumor DNA and matched metastatic tumor N Takahashi, L Pongor, SP Agrawal, M Shtumpf, VN Rajapakse, A Shafiei, ... bioRxiv, 2024.06. 02.597054, 2024 | | 2024 |
| Efficacy of ATR inhibitor berzosertib plus topotecan or topotecan alone in patients with relapsed small cell lung cancer: A randomized clinical trial N Takahashi, Z Hao, LC Villaruz, J Zhang, J Ruiz, WJ Petty, H Mamdani, ... MOLECULAR CANCER THERAPEUTICS 22 (12), 2023 | | 2023 |
| Berzosertib plus topotecan vs topotecan alone in patients with relapsed small cell lung cancer: a randomized clinical trial N Takahashi, Z Hao, LC Villaruz, J Zhang, J Ruiz, WJ Petty, H Mamdani, ... JAMA oncology 9 (12), 1669-1677, 2023 | 10 | 2023 |
| Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: a phase I clinical trial ML Abel, N Takahashi, C Peer, CE Redon, S Nichols, R Vilimas, MJ Lee, ... Clinical Cancer Research 29 (18), 3603-3611, 2023 | 8 | 2023 |
| ATR inhibition augments the efficacy of lurbinectedin in small‐cell lung cancer CW Schultz, Y Zhang, R Elmeskini, A Zimmermann, H Fu, Y Murai, ... EMBO Molecular Medicine 15 (8), e17313, 2023 | 12 | 2023 |
| Severe autoimmune intravascular hemolytic anemia in patients receiving alemtuzumab for multiple sclerosis P Sharma, A Saksena, A Diaz, Y Pang, P Desai Blood Advances 7 (11), 2534-2537, 2023 | 1 | 2023 |
| Dissecting small cell lung cancer subtypes with cell-free DNA fragmentomes. L Rinaldi, ZL Skidmore, B Alipanahi, G Graham, B Chesnick, N Takahashi, ... Journal of Clinical Oncology 41 (16_suppl), 8592-8592, 2023 | | 2023 |
| Abstract CT268: Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: A phase I clinical trial ML Abel, N Takahashi, P Desai, C Peer, C Redon, S Nichols, R Vilimas, ... Cancer Research 83 (8_Supplement), CT268-CT268, 2023 | | 2023 |
| Distinct immunosuppressive tumor microenvironment modulates small cell lung carcinoma neuroendocrine phenotypic plasticity and heterogeneity PA Desai, N Takahashi, Y Cao, C Schultz, D Nousome, D Tillo, ... Cancer Research 83 (7_Supplement), 5828-5828, 2023 | | 2023 |
| Extrachromosomal DNA amplification contributes to small cell lung cancer heterogeneity and is associated with worse outcomes LS Pongor, CW Schultz, L Rinaldi, D Wangsa, CE Redon, N Takahashi, ... Cancer discovery 13 (4), 928-949, 2023 | 28 | 2023 |
| Abstract LB_A10: Efficacy of ATR inhibitor berzosertib plus topotecan or topotecan alone in patients with relapsed small cell lung cancer: A randomized clinical trial N Takahashi, Z Hao, LC Villaruz, J Zhang, J Ruiz, WJ Petty, H Mamdani, ... NaN, LB_A10-LB_A10, 2023 | | 2023 |
| ATR inhibition augments the efficacy of lurbinectedin in small cell lung cancer CW Schultz, Y Zhang, R Elmeskini, A Zimmermann, H Fu, Y Murai, ... bioRxiv, 2022.12. 16.520783, 2022 | 1 | 2022 |
| PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors A Thomas, SD Fontaine, ME Diolaiti, P Desai, R Kumar, N Takahashi, ... Molecular cancer therapeutics 21 (11), 1722-1728, 2022 | 5 | 2022 |
